Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials

References

• Katz N, Krupa D, Sperling R, Espinoza 0, Bravo G. Onset of the rofecoxib treatment response in the chronic low back pain model: an analysis from two four-week, randomized, placebo-controlled, trials. J Clin Rheumatol 2002;8:S57
   Google Scholar
• Laska EM, Siegel C, Sunshine A. Onset and duration: measurement and analysis [Chapter 31], advances in pain research and therapy, vol 18. New York: Raven Press Ltd, 1991. p. 691–8
   Google Scholar
• Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodein in combination with NSAIDs: a randomized study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:23–31
   Google Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831–6
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Moore RA. Antidepressants and chronic pain. BMJ 1997;314:763–4
   PubMed Web of Science ®Google Scholar
• Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781–7
   PubMed Web of Science ®Google Scholar
• Borenstein DG. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr Opin Rheumatol 2000;12:143–9
   PubMed Web of Science ®Google Scholar
• van Tulder MW Scholten RJ, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane collaboration back review group. Spine 2000;25:2501–13
   PubMed Web of Science ®Google Scholar
• Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine 1996;21:2840–50
   PubMed Web of Science ®Google Scholar
• Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998;23:2591–600
   Google Scholar
• Portenoy RK. Current pharmacotherapy of chronic pain. J Pain Symptom Manage 2000;19:516–520
   Web of Science ®Google Scholar
• Schnitzer TJ, Gray WL, Zorba Paster R, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772–8
   PubMed Web of Science ®Google Scholar
• van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of randomized controlled trials of the most common interventions. Spine 1997;22:2128–56
   Google Scholar
• Turner JA, Denny MC. Do antidepressant medications relieve chronic low back pain? J Fam Pract 1993;37:545–53
   PubMed Web of Science ®Google Scholar
• Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998;76:287–96
   PubMed Web of Science ®Google Scholar
• Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137–45
   PubMed Web of Science ®Google Scholar
• Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. J Fam Pract 1982; 14:841–6
   PubMed Web of Science ®Google Scholar
• Hurme M, Himanen P. Diflunisal in the treatment of low back pain in a multicentre study. Int J Clin Pharmacol Res 1986;6:53–8
   PubMedGoogle Scholar
• Berry H, Bloom B, Hamilton EB, Swinson DR. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. Ann Rheum Dis 1982;41:129–32
   PubMed Web of Science ®Google Scholar
• Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94: 504
   Google Scholar
• Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943–53
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978–87
   PubMed Web of Science ®Google Scholar
• Reicin A, Brown J, Jova M, et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgey pain. Am J Orthop 2001;30:40–8
   PubMedGoogle Scholar
• Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxgenase 2 inhibitor shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124–34
   PubMedGoogle Scholar
• Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776–83
   PubMed Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JANIA 1999;282:1929–33
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Eng J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Watson DJ, Harper SE, Zhao P-L, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160: 2998–3003
   Google Scholar
• Katz NP, Ju WD, Krupa DA, et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine 2003;28:851–8
   PubMed Web of Science ®Google Scholar
• Spitzer WO, et al. Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Report of the Quebec Task Force on Spinal Disorders. Spine 1987;12:S1–59
   Google Scholar
• Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277–84
   Google Scholar
• Vioxx package insert, Merck & Co., Inc., Whitehouse Station, NJ 08890
   Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287–94
   Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–58
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Moore RA. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998
   Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain — diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524–34.
   PubMed Web of Science ®Google Scholar